Synthesis of Cyclic Guanidines via Pd-Catalyzed Alkene Carboamination

Blane P. Zavesky, Nicholas R. Babij, Jonathan A. Fritz and John P. Wolfe*

Department of Chemistry, University of Michigan, 930 N. University Avenue, Ann Arbor, Michigan 48109-1055

Supporting Information

Experimental procedures and characterization data for new compounds in Tables 1–3 and Equations 1–2.

Table of Contents

General Considerations	S1
Preparation and Characterization of Guanidine Substrates	S2
Preparation and Characterization of Cyclic Guanidine Products	S7
Deprotection of Cyclic Guanidine Product 18	S18
Structural Assignment of Deprotected Cyclic Guanidine Product 27	S18
Stereochemical Analysis of Enantioenriched Cyclic Guanidine Product 18	S20
References	S23
Copies of NMR Spectra	S24

General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware unless otherwise noted. Tris(dibenzylidene)acetone dipalladium and Nixantphos were purchased from Strem Chemical Co. and used without purification. All other reagents were obtained from commercial sources and were used as obtained unless otherwise noted. (*Z*)-1-bromobutene¹ was prepared according to a slight modification of a literature procedure; the preparation was conducted at rt instead of using microwave heating. *N*-methylbut-2-en-1-ylamine was prepared as a 7:1 mixture of *E:Z* alkene isomers according to a published procedure.² Sodium *tert*-butoxide was kept in a glove box and removed only prior to use. Toluene, THF, diethyl ether and dichloromethane were purified using a GlassContour solvent purification system. Yields refer to isolated yields of compounds estimated to be \geq 95% pure as determined by ¹H NMR analysis unless otherwise noted. The yields reported in the supporting information may differ from those shown in Tables 1–3 and Equation 1 are averages of yields for two or more experiments. Thus, the yields reported in the supporting information may differ from those shown in Tables 1–3 and Equation 1.



*N*¹-Allyl-*N*²,*N*³-Bis(*tert*-butoxycarbonyl)-*N*¹-methylguanidine (3). The title compound was prepared using the general guanylation procedure reported by Lipton.³ A flame-dried flask equipped with a stirbar was cooled under a stream of N₂, and charged with *N*,*N*'-bis-Bocthiourea (1.79 g, 6.45 mmol), dichloromethane (65 mL), *N*-methylallylamine (518 µL, 5.4 mmol), triethylamine (1.66 mL, 11.9 mmol), and *N*-methyl-2-chloropyridinium iodide (1.64 g, 6.42 mmol). The resulting solution was stirred overnight (16 h) at rt. Water was added to the reaction flask, the mixture was stirred at rt for 5 min, then was transferred to a separatory funnel. The layers were separated and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 660 mg (39%) of the title compound as a white solid: mp = 71–74 °C. This compound was found to exist as a mixture of rotamers as judged by ¹H and ¹³C NMR analysis; data are for the mixture. ¹H NMR (700 MHz, CDCl₃) δ 10.05 (s, 1 H), 5.86–5.81 (m, 1 H), 5.26–5.21 (m, 2 H), 4.08 (s, br, 2 H), 2.96 (s, 3 H), 1.49 (s, 18 H); ¹³C NMR (175 MHz, CDCl₃) δ 182.0, 162.6, 155.9, 151.2, 132.7, 118.5, 84.2, 81.9, 79.4, 53.4, 36.4, 28.1, 27.9; IR (film) 3286, 3175, 1748, 1612 cm⁻¹. MS (ESI) 314.2073 (314.2074 calcd for C₁₅H₂₇N₃O₄, M + H⁺).



N,N'-Methanediylidene-bis-(4-methoxyaniline) (S1). The title compound was prepared using a procedure published by Coppola.⁴ A flame-dried flask was cooled under a stream of N₂, charged with 1,3-bis(4-methoxyphenyl)thiourea (5.67 g, 19.6 mmol), 4-dimethylaminopyridine (96.0 mg, 0.786 mmol), methanesulfonyl chloride (1.7 mL, 21.6 mmol), triethylamine (8.2 mL, 58.9 mmol), and dichloromethane (196 mL, 0.1 M). The resulting solution was stirred at 0 °C for 5 min. The solution was then filtered through a plug of silica gel, and the silica gel was washed with 300 mL of a 1:1 mixture of ethyl acetate and hexanes. The filtrate was concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 3.98 g (80%) of the title compound as a white solid. Spectroscopic properties were identical to those previously reported:⁵ mp = 48–50 °C (lit.⁵ mp = 48–50 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, J = 8.8 Hz, 4 H), 6.85 (d, J = 8.8 Hz, 4 H), 3.80 (s, 6 H).

General Procedure for Synthesis of Bis(4-methoxyphenyl)guanidine Substrates. The bis(4-methoxyphenyl)guanidine derivatives were synthesized using a modification of a procedure published by Xi.⁶ A flame dried round-bottom flask equipped with a stirbar was cooled under a stream of N₂, and charged with *N*,*N*¹-methanediylidene-bis-(4-methoxyaniline) (1.0 equiv), the appropriate amine (1.2 equiv), zinc chloride (1 equiv), dichloromethane (0.025 M), and diethyl ether (0.25 M). The resulting mixture was stirred overnight at rt, then was filtered through a plug of celite, and the celite plug was washed with dichloromethane (150 mL). The filtrate was washed with 1M aqueous HCI (5 mL/mmol) and saturated aqueous sodium chloride (5 mL/mmol). The organic layer was then concentrated *in vacuo* and the resulting crude product was purified by flash chromatography on silica gel.



1-AllyI-2,3-bis(4-methoxyphenyI)-1-methylguanidine hydrochloride (4). The title compound was prepared from *N*,*N*'-methanediylidene-bis-(4-methoxyaniline) (1.68 g, 6.61 mmol) and *N*-methylallylamine (0.8 mL, 7.93 mmol) according to the general procedure. This procedure afforded 1.43 g (60%) of the title compound as a white foam solid: mp = 77–79 °C. ¹H NMR (500 MHz, CDCl₃) δ 10.03 (s, 2 H), 7.00 (d, *J* = 9.0 Hz, 4 H), 6.55 (d, *J* = 8.0 Hz, 4 H), 5.88–5.78 (m, 1 H), 5.31–5.21 (m, 2 H), 4.13 (s, 2 H), 3.64 (s, 6 H), 3.08 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 157.0, 154.2, 131.4, 129.7, 123.7, 120.3, 114.1, 55.4, 55.3, 38.1; IR (film) 3203, 1625 cm⁻¹. MS (ESI) 326.1863 (326.1866 calcd for C₁₉H₂₄N₃O₂, M⁺).



1-Ethyl-2,3-bis(4-methoxyphenyl)-1-(2-methylallyl)guanidine hydrochloride (9). The title compound was prepared from *N*,*N*'-methanediylidene-bis-(4-methoxyaniline) (2.06 g, 8.09 mmol) and *N*-ethyl-2-methylallylamine (1.28 mL, 9.7 mmol) according to the general procedure except the *N*-ethyl-2-methylallylamine was filtered through a plug of silica gel prior to addition, and the silica plug was eluted with 5 mL of dichloromethane, which was added to the reaction mixture. This procedure afforded 2.43 g (73%) of the title compound as a white foam solid: mp = 68 °C. ¹H NMR (500 MHz, CDCl₃) δ 6.92 (d, *J* = 8.0 Hz, 4 H), 6.56 (d, *J* = 8.0 Hz, 4 H), 4.99 (s, 1 H), 4.92 (s, 1 H), 4.09 (s, 2 H), 3.66 (s, 6 H), 3.63–3.58 (m, 2 H), 1.74 (s, 3 H), 1.17 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 156.8, 153.9, 139.7, 129.9, 123.6, 114.5, 114.0, 55.9, 55.3, 45.4, 20.3, 13.2; IR (film) 3040, 1619 cm⁻¹. MS (ESI) 354.2180 (354.2176 calcd for C₂₁H₂₈N₃O₂, M⁺).



1-Cinnamyl-2,3-bis(4-methoxyphenyl)-1-methylguanidine hydrochloride (10a). The title compound was prepared from commercially available cinnamyl bromide via a two-step procedure. A round-bottom flask equipped with a stirbar was charged with cinnamyl bromide (5.9 g, 30 mmol) and ethanol (30 mL) and cooled to 0 °C. Methylamine (37.5 mL, 300 mmol, 33% solution in ethanol) was slowly added to the reaction flask over the course of 10 min. The reaction mixture was allowed to warm rt and was stirred overnight. The reaction mixture was concentrated, dissolved in dichloromethane (100 mL), and transferred to a separatory funnel. 1 M HCl (20 mL) was added to the separatory funnel and the layers were separated. The organic layer was washed again with 1 M HCl (20 mL). The combined aqueous layers were transferred to a round-bottom flask and dichloromethane (50mL) was added. The biphasic mixture was basified with NH₄OH to pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with dichloromethane (3 x 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated

in vacuo. The crude *N*-methylcinnamylamine was then coupled with *N*,*N*-methanediylidene-bis-(4-methoxyaniline) (4.3 g, 17.0 mmol) according to the general procedure described above. This procedure afforded 1.82 g (27%) of the title compound as a off-white solid: mp = 84–89 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.70 (s, br, 2 H), 7.33–7.20 (m, 5 H), 7.18 (d, *J* = 9.0 Hz, 4 H), 6.75 (d, *J* = 8.5 Hz, 4 H), 6.49 (d, *J* = 16.5 Hz, 1 H), 6.02–5.97 (m, 1 H), 4.15 (s, br, 2 H), 3.67 (s, 6 H), 2.99 (s, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 157.6, 154.8, 135.8, 135.6, 129.3, 128.6, 128.1, 126.7, 124.4, 121.6, 114.7, 55.4, 54.9, 37.7; IR (film) 3256, 3205, 1627 cm⁻¹. MS (ESI) 402.2176 (402.2176 calcd for C₂₅H₂₈N₃O₂, M⁺).



1-(But-2-en-1-yl)-2,3-bis(4-methoxyphenyl)-1-methylguanidine hydrochloride (10b). The title compound was prepared from *N,N*-methanediylidene-bis-(4-methoxyaniline) (778 mg, 3.06 mmol) and *N*-methylbut-2-en-1-amine (employed as a 7:1 mixture of *E:Z* alkene isomers and as a 20% solution in EtOH) (260 mg, 3.06 mmol, 1.0 equiv,) according to the general procedure. After purification by flash column chromatography, 448 mg (39%) of the title compound was obtained as a pale brown solid (mp: 58–63 °C) and as a 7:1 mixture of *E:Z* alkene isomers as determined by ¹H NMR analysis. The ¹H data contains dichloromethane which was difficult to remove *in vacuo*. The data is for the mixture. ¹H NMR (500 MHz, CDCl₃) δ 8.57 (s, 2 H), 7.17–7.13 (m, 4 H), 6.81–6.78 (m, 4 H), 5.73–5.66 (m, 1 H), 5.37–5.32 (m, 1 H), 3.93 (d, *J* = 5 Hz, 2 H), 3.73 (s, 6 H), 2.92 (s, 3 H), 1.69 (d, *J* = 5.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 157.7, 157.4, 154.5, 133.0, 131.2, 129.3, 125.0, 124.3, 123.1, 114.7, 114.7, 55.5, 55.5, 54.7, 37.6, 17.8; IR (film) 3247, 2954, 1627 cm⁻¹. MS (ESI) 340.2019 (340.2020 calcd for C₂₀H₂₅N₃O₂, M⁺).



(±)-*N*,*N*'-Bis(4-methoxyphenyl)-2-vinylpyrrolidine-1-carboximidamide hydrochloride (11). The title compound was prepared from commercially available *N*-Boc-2-vinylpyrrolidine via a two-step procedure. A round-bottom flask equipped with a stirbar was charged with *N*-Boc-2vinylpyrrolidine (2.5 mL, 12.5 mmol) and dichloromethane (25 mL). Trifluoroacetic acid (12.5 mL, 1.0 M) was added to the flask and the mixture was stirred at rt for 1 h until the starting material had been completely consumed as judged by TLC analysis. The solution was diluted with water, basified with NH₄OH to pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with dichloromethane (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude amine was then coupled with *N*,*N*-methanediylidene-bis-(4-methoxyaniline) (3.2 g, 12.5 mmol) according to the general procedure described above. This procedure afforded 464 mg (10%) of the title compound as a pale yellow solid: mp = 58–62 °C. ¹H NMR (700 MHz, CD₃OD) δ 7.00 (d, *J* = 9.1 Hz, 4 H), 6.82 (d, *J* = 9.1 Hz, 4 H), 5.90–5.85 (m, 1 H), 2.30–2.26 (m, 1 H), 2.08–2.04 (m, 1 H), 2.01–1.95 (m, 1 H), 1.87–1.82 (m, 1 H); ¹³C NMR (175 MHz, CD₃OD) δ 159.4, 153.8, 137.6, 130.7, 125.9, 118.4, 115.6, 63.5, 56.0, 51.4, 33.7, 25.0; IR (film) 3204, 1629 cm⁻¹. MS (ESI) 352.2020 (352.2020 calcd for C₂₁H₂₆N₃O₂, M⁺).



1-AllyI-1-methylguanidinium trifluoroacetate (28). A round-bottom flask equipped with a stirbar was charged with **3** (196 mg, 0.63 mmol) and dichloromethane (2.4 mL). Trifluoroacetic acid (0.9 mL) was added to the flask and the reaction mixture was stirred overnight at rt, and the solution was then concentrated *in vacuo*. Toluene (4 mL) was added and the resulting solution was concentrated *in vacuo*. The addition of toluene and subsequent concentration was repeated (3x) to remove all excess trifluoroacetic acid, at which time the compound was obtained as a crystalline white solid: mp = 159–164 °C. This procedure afforded 85 mg (60%) of the title compound. This material also contained ca. 10% of an unidentified side product. ¹H NMR (500 MHz, CD₃OD) δ 5.83–5.75 (m, 1 H), 5.26–5.17 (m, 2 H), 3.95 (d, 2 H), 2.99 (s, 3 H); ¹³C NMR (125 MHz, CD₃OD) δ 159.4, 132.8, 118.9, 45.4, 37.3; IR (film) 3312, 3150, 1663 cm⁻¹. MS (ESI) 114.1028 (114.1026 calcd for C₅H₁₁N₃, M⁺).

Preparation and Characterization of Cyclic Guanidine Products

General Procedure for the Pd-Catalyzed Synthesis of Cyclic Guanidines. A flame-dried Schlenk tube was cooled under vacuum and charged with the appropriate guanidine substrate (1.0 equiv), Pd₂(dba)₃ (0.02 equiv), Nixantphos (0.08 equiv), and NaO*t*Bu (2.4 equiv). The flask was evacuated and backfilled with N₂. Toluene (0.1 M) was added via syringe and the resulting mixture was stirred at rt for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was heated to 107 °C and stirred overnight (~16 h). The mixture was cooled to room temperature and 1 M HCl (10 mL/mmol substrate) and dichloromethane (25 mL/mmol substrate) were added. The layers were separated and the aqueous layer was extracted with dichloromethane (10 mL/mmol). The organic layers were combined and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel.

General Procedure for the Asymmetric Pd-Catalyzed Synthesis of Enantioenriched Cyclic Guanidines. A flame-dried Schlenk tube was cooled under vacuum and charged with the guanidine substrate **9** (1.0 equiv), $Pd_2(dba)_3$ (0.02 equiv), the appropriate ligand (0.08 equiv for monodenate ligands, and 0.16 equiv for bidendate ligands), and NaO*t*Bu (2.4 equiv). The flask was evacuated and backfilled with N₂. Toluene (0.1 M) was added via syringe and the resulting mixture was stirred at rt for 2 min. 4-bromotoluene (1.5 equiv) was added and the tube was heated to 107 °C and stirred overnight (~16 h). The mixture was cooled to room temperature and 1 M HCl (10 mL/mmol substrate) and dichloromethane (25 mL/mmol substrate) were added. The layers were separated and the aqueous layer was extracted with dichloromethane (10 mL/mmol). The organic layers were combined and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel.



tert-Butyl-2-[(tert-butoxycarbonyl)imino]-3-methyl-5-(naphthalen-2-

ylmethyl)imidazolidine-1-carboxylate (5). The general procedure was employed for the coupling of **3** (94 mg, 0.3 mmol) and 2-bromonaphthalene (93 mg, 0.45 mmol) using a catalyst composed of Pd_2dba_3 (5.5 mg, 0.006 mmol) and Nixantphos (13 mg, 0.024 mmol). Saturated aqueous NH_4CI was used during the workup instead of 1 M HCl. This procedure afforded 43 mg

(33%) of the title compound as an off-white solid: mp = 56–58 °C. This compound was found to exist as a mixture of rotamers as judged by ¹H and ¹³C NMR analysis; data are for the mixture. ¹H NMR (700 MHz, CDCl₃) δ 7.81–7.79 (m, 3 H), 7.70 (s, 1 H), 7.48–7.43 (m, 2 H), 7.36 (dd, *J* = 1.4, 8.4 Hz, 1 H), 4.47–4.44 (m, 1 H), 3.44–3.40 (m, 1 H), 3.35 (dd, *J* = 4.9, 14.0 Hz, 1 H), 3.07 (dd, *J* = 2.1, 9.8 Hz, 1 H), 2.93 (dd, *J* = 9.1, 14.0 Hz, 1 H), 2.83 (s, 3 H), 1.54 (s, 9 H), 1.45 (s, 9 H); ¹³C NMR (175 MHz, CDCl₃) δ 159.6, 151.5, 149.8, 133.9, 133.5, 132.4, 128.4, 128.2, 127.6, 127.6, 127.5, 126.2, 125.8, 82.5, 78.7, 56.7, 49.9, 40.2, 32.1, 28.3, 28.1; IR (film) 1748, 1629 cm⁻¹. MS (ESI) 440.2538 (440.2544 calcd for C₂₅H₃₃N₃O₄, M + H⁺).



tert-Butyl 2-[(*tert*-butoxycarbonyl)imino]-3-methyl-5-(4-methylbenzyl)imidazolidine-1carboxylate (6). The general procedure was employed for the coupling of **3** (63 mg, 0.2 mmol) and 4-bromotoluene (51 mg, 0.3 mmol) using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol) and Nixantphos (8.8 mg, 0.016 mmol). Saturated aqueous NH₄Cl was used during the workup instead of 1 M HCl. This procedure afforded 21 mg (26%) of the title compound as a pale yellow oil. This compound was found to exist as a mixture of rotamers as judged by ¹H and ¹³C NMR analysis; data are for the mixture. ¹H NMR (700 MHz, CDCl₃) δ 7.12 (d, *J* = 7.7 Hz, 2 H), 7.09 (d, *J* = 7.7 Hz, 2 H), 4.29–4.26 (m, 1 H), 3.25–3.21 (m, 2 H), 3.04 (dd, *J* = 2.8, 9.1 Hz, 1 H), 2.76 (s, 3 H), 2.65 (dd, *J* = 9.8, 13.3 Hz, 1 H), 2.32 (s, 3 H), 1.57 (s, 9 H), 1.45 (s, 9 H); ¹³C NMR (175 MHz, CDCl₃) δ 165.5, 154.1, 150.6, 136.5, 133.3, 129.4, 129.2, 82.3, 53.2, 47.7, 39.0, 30.5, 28.2, 21.0; IR (film) 1750, 1627 cm⁻¹. MS (ESI) 404.2545 (404.2544 calcd for C₂₂H₃₃N₃O₄, M + H⁺).



N,3-Bis(4-methoxyphenyl)-1-methyl-4-(naphthalen-2-ylmethyl)imidazolidin-2-imine hydrochloride (7): The general procedure was employed for the coupling of 4 (54 mg, 0.15

mmol) and 2-bromonaphthalene (47 mg, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 42 mg (57%) of the title compound as a pale yellow-brown foam solid: mp = 67–68 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.80–7.77 (m, 3 H), 7.60 (s, 1 H), 7.50–7.46 (m, 2 H), 7.21 (d, *J* = 8.0 Hz, 1 H), 7.04–7.02 (m, 2 H), 6.97–6.94 (m, 2 H), 6.63–6.60 (m, 2 H), 6.52–6.49 (m, 2 H), 4.50–4.44 (m, 1 H), 3.83–3.79 (m, 1 H), 3.70–3.68 (m, 3 H), 3.39–3.36 (m, 3 H), 3.61–3.59 (m, 1 H), 3.39–3.62 (m, 3 H), 3.23–3.19 (m, 1 H), 3.04 (dd, *J* = 10.0, 13.0 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.2, 157.7, 156.5, 133.4, 132.5, 132.4, 132.4, 132.3, 129.5, 128.8, 128.0, 127.7, 127.5, 126.9, 126.6, 126.6, 126.1, 114.6, 113.8, 63.8, 55.5, 55.4, 54.0, 39.5, 35.7; IR (film) 3050, 1632 cm⁻¹. MS (ESI) 452.2328 (452.2333 calcd for C₂₉H₃₀N₃O₂, M⁺).



N,3-Bis(4-methoxyphenyl)-1-methyl-4-(4-methylbenzyl)imidazolidin-2-imine hydrochloride (8): The general procedure was employed for the coupling of **4** (54 mg, 0.15 mmol) and 4iodotoluene (49 mg, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 42 mg (62%) of the title compound as a pale yellow-brown foam solid: mp = 73–75 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.14 (d, *J* = 8.5 Hz, 2 H), 7.11–7.06 (m, 4 H), 7.02 (d, *J* = 8.0 Hz, 2 H), 6.67 (d, *J* = 9.0 Hz, 2 H), 6.56 (d, *J* = 9.0 Hz, 2 H), 4.49–4.42 (m, 1 H), 3.90–3.86 (m, 1 H), 3.72 (s, 3 H), 3.66 (s, 3 H), 3.60 (dd, *J* = 7.5, 10.0 Hz, 1 H), 3.23 (s, 3 H), 2.96 (dd, *J* = 4.5, 13.5 Hz, 1 H), 2.91 (dd, *J* = 10.0, 13.5 Hz, 1 H), 2.30 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.4, 158.2, 156.1, 137.0, 131.8, 129.6, 129.2, 129.0, 128.7, 127.7, 126.9, 114.8, 113.9, 63.6, 55.6, 55.5, 54.2, 38.4, 36.2, 21.0; IR (film) 3133, 1631 cm⁻¹. MS (ESI) 416.2340 (416.2333 calcd for C₂₆H₃₀N₃O₂, M⁺).



N,3-Bis(4-methoxyphenyl)-1-methyl-4-(4-methylbenzyl)imidazolidin-2-imine hydrochloride (8): The general procedure was employed for the coupling of 4 (54 mg, 0.15 mmol) and 4bromotoluene (39 mg, 0.225 mmol) using a catalyst composed of Pd_2dba_3 (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 50 mg (73%) of the title compound as a pale yellow-brown foam solid. Spectroscopic data were identical to those provided above.



4-[4-(1*H***-Pyrrol-1-yl]benzyl)-***N***,3-bis(4-methoxyphenyl)-1-methylimidazolidin-2-imine hydrochloride (12): The general procedure was employed for the coupling of 4** (54 mg, 0.15 mmol) and 1-(4-iodophenyl)pyrrole (61 mg, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 48 mg (63%) of the title compound as a pale yellow-brown foam solid: mp = 70-71 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, *J* = 8.0 Hz, 2 H), 7.21–7.17 (m, 4 H), 7.14 (d, *J* = 8.5 Hz, 2 H), 7.04 (t, *J* = 2.5 Hz, 2 H), 6.69 (d, *J* = 9.0 Hz, 2 H), 6.58 (d, *J* = 9.0 Hz, 2 H), 6.33 (t, *J* = 3.0 Hz, 2 H), 4.58–4.51 (m, 1 H), 3.95–3.91 (m, 1 H), 3.72 (s, 3 H), 3.70–3.68 (m, 1 H), 3.67 (s, 3 H), 3.22 (s, 3 H), 3.06–3.04 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.4, 158.2, 156.2, 139.8, 132.4, 130.3, 129.3, 128.6, 127.7, 127.0, 120.7, 119.2, 114.8, 113.9, 110.6, 63.5, 55.6, 55.5, 54.3, 38.2, 36.0; IR (film) 3058, 1635 cm⁻¹. MS (ESI) 467.2450 (467.2442 calcd for C₂₉H₃₁N₄O₂, M⁺).



4-Benzyl-*N***,3-bis(4-methoxyphenyl)-1-methylimidazolidin-2-imine hydrochloride (13)**: The general procedure was employed for the coupling of **4** (54 mg, 0.15 mmol) and bromobenzene (24 μ L, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 48 mg (73%) of the title compound as a pale yellow-brown foam solid: mp = 58–59 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.31 (t, *J* = 7.0

Hz, 2 H), 7.27–7.26 (m, 1 H), 7.13 (d, J = 8.0 Hz, 2 H), 6.98 (d, J = 9.0 Hz, 2 H), 6.92 (d, J = 9.0 Hz, 2 H), 6.61 (d, J = 8.5 Hz, 2 H), 6.50 (d, J = 9.0 Hz, 2 H), 4.34–4.27 (m, 1 H), 3.83–3.78 (m, 1 H), 3.69 (s, 3 H), 3.65 (s, 3 H), 3.51 (dd, J = 3.5, 13.5 Hz, 1 H), 3.40 (s, 3 H), 3.06 (dd, J = 3.5, 13.5 Hz, 1 H), 2.85 (dd, J = 10.0, 14.0 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.0, 157.5, 156.5, 135.0, 129.9, 129.1, 129.0, 128.6, 128.3, 127.5, 126.5, 114.5, 113.8, 63.9, 55.5, 55.5, 53.8, 39.5, 35.4; IR (film) 3003, 1640 cm⁻¹. MS (ESI) 402.2177 (402.2176 calcd for C₂₅H₂₈N₃O₂, M⁺).



[4-{3-(4-Methoxyphenyl)-2-[(4-methoxyphenyl)imino]-1-methylimidazolidin-4-

ylmethyl}phenyl](phenyl)methanone hydrochloride (14): The general procedure was employed for the coupling of **4** (54 mg, 0.15 mmol) and 4-iodobenzophenone (69 mg, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 56 mg (69%) of the title compound as a pale yellowbrown foam solid: mp = 70–71 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.75 (s, 1 H), 7.73 (d, *J* = 8.0 Hz, 2 H), 7.67 (d, *J* = 7.0 Hz, 2 H), 7.59 (t, *J* = 8.0 Hz, 1 H), 7.48 (t, *J* = 7.5 Hz, 2 H), 7.30 (d, *J* = 8.5 Hz, 2 H), 7.20 (d, 7.5 Hz, 2 H), 7.15 (d, *J* = 8.0 Hz, 2 H), 6.67 (d, *J* = 7.5 Hz, 2 H), 6.57 (d, *J* = 7.5 Hz, 2 H), 4.72–4.65 (m, 1 H), 4.02–3.98 (m, 1 H), 3.76–3.73 (m, 1 H), 3.70 (s, 3 H), 3.65 (s, 3 H), 3.23 (s, 3 H), 3.21–3.17 (m, 1 H), 3.10 (dd, *J* = 4.5, 13.5 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 196.2, 159.5, 158.3, 156.1, 140.2, 137.3, 136.3, 132.6, 130.5, 129.9, 129.5, 129.2, 128.3, 128.2, 128.0, 126.6, 114.8, 113.9, 63.1, 55.6, 55.5, 54.4, 38.8, 36.1; IR (film) 3135, 1655, 1630 cm⁻¹. MS (ESI) 506.2437 (506.2438 calcd for C₃₂H₃₂N₃O₃, M⁺).



4-(Benzo[*d***][1,3]dioxol-5-ylmethyl)**-*N*,**3-bis(4-methoxyphenyl)**-**1-methylimidazolidin-2imine hydrochloride (15):** The general procedure was employed for the coupling of **4** (54 mg, 0.15 mmol) and 4-bromo-1,2-(methylenedioxy)benzene (27 µL, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 59 mg (81%) of the title compound as a pale yellow-brown foam solid: mp = 66-68 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.01 (d, *J* = 9.1 Hz, 2 H), 6.92 (d, *J* = 9.1 Hz, 2 H), 6.73 (d, *J* = 7.7 Hz, 1 H), 6.61–6.58 (m, 4 H), 6.51 (d, *J* = 9.1 Hz, 2 H), 5.93 (s, 2 H), 4.31–4.26 (m, 1 H), 3.84–3.81 (m, 1 H), 3.70 (s, 3 H), 3.65 (s, 3 H), 3.53 (dd, *J* = 7.0, 9.8 Hz, 1 H), 3.39 (s, 3 H), 2.95 (dd, *J* = 4.2, 13.3 Hz, 1 H), 3.78 (dd, *J* = 9.8, 14.0 Hz, 1 H); ¹³C NMR (175 MHz, CDCl₃) δ 159.1, 157.7, 156.4, 148.1, 146.8, 129.6, 128.7, 128.4, 127.8, 126.8, 122.2, 114.5, 113.7, 109.2, 108.6, 101.1, 63.9, 55.5, 55.4, 53.8, 38.9, 35.6; IR (film) 3005, 1640 cm⁻¹. MS (ESI) 446.2077 (446.2074 calcd for C₂₆H₂₈N₃O₄, M⁺).



4-[(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl]-N,3-bis(4-methoxyphenyl)-1-

methylimidazolidin-2-imine hydrochloride (16): The general procedure was employed for the coupling of **4** (54 mg, 0.15 mmol) and 6-bromo-1,4-benzodioxane (30 μL, 0.225 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 67 mg (90%) of the title compound as a pale yellow-brown foam solid: mp = 76–77 °C. ¹H NMR (500 MHz, CDCl₃) δ 6.95 (d, *J* = 9.0 Hz, 2 H), 6.88 (d, *J* = 9.0 Hz, 2 H), 6.78 (d, *J* = 8.0 Hz, 1 H), 6.61–6.57 (m, 4 H), 6.49 (d, *J* = 8.5 Hz, 2 H), 4.29–4.24 (m, 1 H), 4.23 (s, 4 H), 3.84–3.80 (m, 1 H), 3.69 (s, 3 H), 3.64 (s, 3 H), 3.49 (dd, *J* = 7.0, 10.5 Hz, 1 H), 3.39 (s, 3 H), 2.92 (dd, *J* = 4.5, 13.5 Hz, 1 H), 2.72 (dd, *J* = 9.5, 14.0 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.0, 157.5, 156.4, 143.7, 142.9, 129.9, 128.5, 128.3, 127.9, 126.5, 122.0, 117.7, 117.7, 114.5, 113.7, 64.4, 64.3, 63.9, 55.5, 55.4, 53.7, 38.5, 35.3; IR (film) 3000, 1639 cm⁻¹. MS (ESI) 460.2226 (460.2231 calcd for C₂₇H₃₀N₃O₄, M⁺).



N,3-Bis(4-methoxyphenyl)-1-methyl-4-(2-methylbenzyl)imidazolidin-2-imine hydrochloride (17): The general procedure was employed for the coupling of 4 (54 mg, 0.15 mmol) and 2bromotoluene (27 µL, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 52 mg (76%) of the title compound as a pale yellow-brown foam solid. The material contained ca. 8% of an unsaturated cyclic guanidine resulting from oxidation of the title compound (tentatively assigned as the 2-(E)-N,3-bis(4-methoxyphenyl)-1-methyl-4-(2-methylbenzyl)-1,3aminoimidazole derivative dihydro-2*H*-imidazol-2-imine hydrochloride). mp = 78–79 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.15– 7.11 (m, 3 H), 7.08–7.07 (m, 1 H), 7.00 (d, J = 9.1 Hz, 2 H), 6.90 (d, J = 8.4 Hz, 2 H), 6.60 (d, J = 9.1 Hz, 2 H), 6.49 (d, J = 9.1 Hz, 2 H), 4.33–4.29 (m, 1 H), 3.81–3.78 (m, 1 H), 3.69 (s, 3 H), 3.64 (s, 3 H), 3.54 (dd, J = 7.7, 10.5 Hz, 1 H), 3.42 (s, 3 H), 3.06 (dd, J = 4.2, 14.0 Hz, 1 H), 2.81 (dd, J = 10.5, 14.0 Hz, 1 H), 2.10 (s, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 159.0, 157.5, 156.4, 136.3, 133.4, 130.8, 129.6, 129.6, 128.6, 128.2, 127.5, 126.6, 126.4, 114.5, 113.7, 62.6, 55.5, 55.4, 54.1, 36.8, 35.5, 19.3; IR (film) 3002, 1630 cm⁻¹. MS (ESI) 416.2328 (416.2333 calcd for $C_{26}H_{30}N_3O_2$, M⁺).



1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine

hydrochloride (18): The general procedure was employed for the coupling of **9** (59 mg, 0.15 mmol) and 4-bromotoluene (35 mg, 0.23 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 71 mg (99%) of the title compound as a pale yellow-brown foam solid: mp = 61–62 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.18 (d, *J* = 8.0 Hz, 2 H), 7.11 (d, *J* = 8.0 Hz, 2 H), 6.90–6.87 (m, 4 H), 6.61 (d, *J* = 8.5 Hz, 2 H), 6.50 (d, *J* = 8.5 Hz, 2 H), 4.02–3.95 (m, 1 H), 3.87–3.80 (m, 2 H), 3.70 (s, 3 H), 3.65

(s, 3 H), 3.35 (d, J = 10.5 Hz, 1 H), 2.98 (d, J = 13.5 Hz, 1 H), 2.75 (d, J = 13.5 Hz, 1 H), 2.36 (s, 3 H), 1.26–1.20 (m, 6 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.2, 157.3, 155.2, 137.6, 131.5, 130.2, 130.0, 129.5, 128.7, 127.0, 126.2, 114.3, 113.7, 65.7, 55.9, 55.5, 55.5, 45.1, 42.0, 25.3, 21.1, 12.3; IR (film) 2971, 1630 cm⁻¹. MS (ESI) 444.2645 (444.2646 calcd for C₂₈H₃₄N₃O₂, M⁺).



(+)-1-Ethyl-*N*,3-bis(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine hydrochloride (18; prepared using (*S*)-Phanephos as ligand): The general procedure for the asymmetric synthesis of cyclic guanidine products was employed for the coupling of **9** (58.5 mg, 0.15 mmol) and 4-bromotoluene (39 mg, 0.225 mmol) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and (*S*)-Phanephos (6.9 mg, 0.012 mmol) except the reaction was run for 36 hrs in order to ensure complete conversion. This procedure afforded 65.0 mg (84%) of the title compound as a pale yellow-brown foam solid: $[\alpha]^{23}_{D}$ +18.0 (*c* 1.3, CH₂Cl₂). Spectroscopic data were identical to those provided above. The enantiomeric purity was determined to be 61:39 er as assessed by converting this compound to the corresponding Mosher amide (see below for details).



(–)-1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine hydrochloride (18; prepared using (S)-BINAP as ligand): The general procedure for the asymmetric synthesis of cyclic guanidine products was employed for the coupling of **9** (39 mg, 0.1 mmol) and 4-bromotoluene (26 mg, 0.15 mmol) using a catalyst composed of Pd₂dba₃ (1.8 mg, 0.002 mmol), and (S)-BINAP (5.0 mg, 0.008 mmol). This procedure afforded 48 mg (99%) of the title compound as a pale yellow-brown foam solid: $[\alpha]^{23}_{D}$ –5.9 (*c* 0.9, CH₂Cl₂). Spectroscopic data were identical to those provided above. The enantiomeric purity was determined to be 48:52 er as assessed by converting this compound to the corresponding Mosher amide (see below for details).



4-(Benzo[d][1,3]dioxol-5-ylmethyl)-1-ethyl-N,3-bis(4-methoxyphenyl)-4-

methylimidazolidin-2-imine hydrochloride (19): The general procedure was employed for the coupling of **9** (59 mg, 0.15 mmol) and 4-bromo-1,2-(methylenedioxy)benzene (27 μL, 0.225 mmol), using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 76 mg (99%) of the title compound as a pale yellow-brown foam solid: mp = 66–67 °C. ¹H NMR (500 MHz, CDCl₃) δ 6.93–6.83 (m, 4 H), 6.81 (d, *J* = 8.0 Hz, 1 H), 6.71–6.68 (m, 2 H), 6.62 (s, br, 2 H), 6.51 (d, *J* = 8.5 Hz, 2 H), 5.98 (s, 2 H), 4.01–3.94 (m, 1 H), 3.88 (d, *J* = 10.0 Hz, 1 H), 3.84–3.77 (m, 1 H), 3.71 (s, 3 H), 3.66 (s, 3 H), 3.42 (d, *J* = 10.5 Hz, 1 H), 2.96 (d, *J* = 13.5 Hz, 1 H), 2.69 (d, *J* = 13.5 Hz, 1 H), 1.26–1.19 (m, 6 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.3, 157.6, 155.3, 148.0, 147.2, 129.8, 128.1, 128.0, 126.7, 123.6, 114.4, 113.7, 110.4, 108.5, 101.3, 65.8, 55.9, 55.5, 55.5, 45.0, 42.1, 25.3, 12.3; IR (film) 2972, 1627 cm⁻¹. MS (ESI) 474.2379 (474.2387 calcd for C₂₈H₃₂N₃O₄, M⁺).



1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(thiophen-2-ylmethyl)imidazolidin-2-imine hydrochloride (20): The general procedure was employed for the coupling of **9** (59 mg, 0.15 mmol) and 2-bromothiophene (22 μ L, 0.225 mmol), using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 70 mg (99%) of the title compound as a pale yellow-brown foam solid: mp = 63–65 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.31–7.30 (m, 1 H), 7.06–6.97 (m, 6 H), 6.62 (d, *J* = 8.5 Hz, 2 H), 6.49 (d, *J* = 9.5 Hz, 2 H), 3.98–3.87 (m, 2 H), 3.69–3.60 (m, 8 H), 3.24 (d, *J* = 15.5 Hz, 1 H), 3.05 (d, *J* = 15.0 Hz, 1 H), 1.27 (s, 3 H), 1.10 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 159.3, 157.4, 155.2, 136.3, 130.3, 128.4, 128.1, 127.2, 126.7, 126.4, 125.5, 114.4, 113.7, 65.3, 55.9, 55.5, 55.4, 41.9, 39.9, 26.0, 11.9; IR (film) 3041, 1630 cm⁻¹. MS (ESI) 436.2057 (436.2053 calcd for C₂₅H₂₉N₃O₂S, M⁺).



(*Z*)-1-Ethyl-*N*,3-bis(4-methoxyphenyl)-4-methyl-4-(pent-2-en-1-yl)imidazolidin-2-imine hydrochloride (21): The general procedure (using modified stoichiometries of reactants) was used for the coupling of **9** (59 mg, 0.15 mmol) and 1-bromobutene (300 µL, 0.60 mmol, 4.0 equiv, 2 M solution in toluene) using a catalyst composed of Pd₂dba₃ (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol) in the presence of NaO*t*Bu (64.9 mg, 0.60 mmol, 4.5 equiv). This procedure afforded 57 mg (86%) of the title compound as a pale yellow-brown oil. ¹H NMR (700 MHz, CDCl₃) δ 6.99 (s, br, 1 H), 6.92 (d, *J* = 8.4 Hz, 2 H), 6.76 (s, br, 1 H), 6.65–6.53 (m, br, 2 H), 6.49 (d, *J* = 9.1 Hz, 2 H), 5.74–5.70 (m, 1 H), 5.39–5.35 (m, 1 H), 4.10–4.05 (m, 1 H), 3.92–3.86 (m, 1 H), 3.71–3.67 (m, 1 H), 3.68 (s, 3 H), 3.64 (s, 3 H), 3.59 (d, *J* = 9.8 Hz, 1 H), 2.42 (dd, *J* = 6.3, 14.7 Hz, 1 H), 2.28 (dd, *J* = 7.7, 15.4 Hz, 1 H), 2.10–2.06 (m, 2 H), 1.34 (t, *J* = 7.0 Hz, 3 H), 1.25 (s, 3 H), 1.01 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 159.2, 157.3, 155.0, 137.3, 130.5, 129.7, 128.1, 126.3, 120.7, 114.2, 113.7, 65.3, 56.2, 55.4, 55.4, 42.2, 37.1, 25.6, 21.0, 13.9, 12.3; IR (film) 3006, 1627 cm⁻¹. MS (ESI) 408.2643 (408.2646 calcd for C₂₅H₃₄A₃O₂, M⁺).



(±)-(*S**,*S**)-*N*,3-Bis(4-methoxyphenyl)-1-methyl-4-(phenyl(*p*-tolyl)methyl)imidazolidin-2imine hydrochloride (22a). The general procedure was employed for the coupling of **10** (132 mg, 0.3 mmol) and 4-bromotoluene (76 mg, 0.45 mmol), using a catalyst composed of Pd₂dba₃ (5.5 mg, 0.006 mmol), and Nixantphos (13.2 mg, 0.024 mmol). This procedure afforded 35 mg (22%) of the title compound as a pale yellow-brown solid: mp = 91–93 °C. This compound was judged to be a single diastereomer (> 20:1 dr) by ¹H NMR analysis. ¹H NMR (700 MHz, CDCl₃) δ 11.33 (s, br, 1 H), 7.38–7.36 (m, 2 H), 7.31–7.29 (m, 1 H), 7.25–7.24 (m, 2 H), 7.04 (d, *J* = 7.7 Hz, 2 H), 6.99 (d, *J* = 8.4 Hz, 2 H), 6.76 (d, *J* = 9.1 Hz, 2 H), 6.46 (d, *J* = 9.1 Hz, 2 H), 6.40 (s, 4 H), 4.65–4.62 (m, 1 H), 4.35 (d, J = 8.4 Hz, 1 H), 4.15–4.12 (m, 1 H), 3.64 (s, 3 H), 3.63 (s, 3 H), 3.51 (dd, J = 4.9, 11.2 Hz, 1 H), 3.27 (s, 3 H), 2.28 (s, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 158.9, 158.1, 157.7, 139.3, 137.3, 136.6, 132.0, 129.6, 129.2, 128.6, 128.5, 128.2, 128.2, 127.9, 126.3, 114.1, 113.7, 66.7, 55.4, 54.8, 53.3, 35.2, 21.0 (one carbon signal is absent due to incidental equivalence); IR (film) 3105, 1641 cm⁻¹. MS (ESI) 492.2652 (492.2646 calcd for C₃₂H₃₄N₃O₂, M⁺).



(±)-*N*,2,Bis-(4-methoxyphenyl)-1-(4-methylbenzyl)tetrahydro-1*H*-pyrrolo[1,2-c]imidazol-3(2H)-imine hydrochloride (23). The general procedure was employed for the coupling of 11 (77.6 mg, 0.2 mmol) and 4-bromotoluene (52 mg, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.6 mg, 0.004 mmol), and Nixantphos (8.8 mg, 0.016 mmol). This procedure afforded a crude mixture that was determined to be a 1.5:1 mixture of diastereomers by ¹H NMR analysis. After purification by flash column chromatography 53 mg (60%) of the title compound was obtained as a pale brown solid and as a 2:1 mixture of diastereomers as determined by ¹H NMR analysis. The data is for the mixture except the ¹H NMR data, which is only for the major isomer: mp = 58–61 °C. ¹H NMR (700 MHz, CDCl₃) δ 10.94, (s, br, 1 H), 7.21–7.14 (m, 4 H), 7.12–7.08 (m, 2 H), 6.97 (d, J = 8.4 Hz, 2 H), 6.84–6.80 (m, 2 H), 6.68–6.67 (m, 2 H), 4.50–4.47 (m, 1 H), 3.95–3.92 (m, 1 H), 3.77 (s, 3 H), 3.71 (s, 3 H), 3.45–3.44 (m, 1 H), 3.35–3.32 (m, br, 1 H), 2.98 (dd, J = 3.5, 13.3 Hz, 1 H), 2.53 (dd, J = 11.2, 14.0 Hz, 1 H), 2.31 (s, 3 H), 2.07–2.03 (m, 1 H), 1.87–1.79 (m, 1 H), 1.62–1.58 (m, 2 H); 13 C NMR (175 MHz, CDCl₃) δ 159.6, 159.5, 157.8, 157.7, 137.0, 136.8, 132.4, 131.7, 129.7, 129.5, 129.4, 128.8, 128.4, 128.0, 126.6, 126.0, 125.4, 115.1, 115.1, 114.1, 68.4, 66.2, 64.9, 64.6, 55.5, 55.4, 49.3, 48.7, 38.2, 35.2, 31.2, 26.7, 26.2, 25.8, 21.0, 20.0; IR (film) 1625 cm⁻¹. MS (ESI) 442.2484 (442.2489 calcd for $C_{28}H_{32}N_3O_2$, M⁺).

Deprotection of Cyclic Guanidine Product 18



1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine

hydrochloride (27). A Schlenk tube was charged with a stirbar, **18** (48 mg, 0.1 mmol) and CH₃CN (1 mL). A solution of ceric ammonium nitrate (329 mg, 0.6 mmol) in H₂O (6 mL) was added to the reaction flask and the mixture was stirred at rt for 5 min. The mixture was then heated at 50 °C for 12 h before being cooled to rt, at which time dichloromethane (15 mL) was added. The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with saturated Na₂SO₃ (10 mL), saturated aqueous NaHCO₃ (10 mL), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 14.6 mg (39%) of the title compound as white solid: mp = 223–226 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.19 (s, br 2 H), 7.13 (d, J = 7.7 Hz, 2 H), 7.03 (d, *J* = 9.1 Hz, 2 H), 6.98 (d, *J* = 7.7 Hz, 2 H), 3.91–3.88 (m, 1 H), 3.88 (s, 3 H), 3.84–3.81 (m, 1 H), 3.77 (d, *J* = 9.8 Hz, 1 H), 3.18 (d, *J* = 9.8 Hz, 1 H), 2.94 (d, *J* = 13.3 Hz, 1 H), 2.70 (d, *J* = 13.3 Hz, 1 H), 2.33 (s, 3 H), 1.31 (s, 3 H) 1.25 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 161.1, 155.9, 137.5, 131.4 (br, 1 C), 131.3, 129.9, 129.6, 123.5, 115.8, 65.8, 55.7, 55.6, 43.7, 41.3, 23.9, 21.0, 12.2; IR (film) 3250, 1658 cm⁻¹. MS (ESI) 338.2228 (338.2227 calcd for C₂₁H₂₈N₃O, M⁺).

Structural Assignment of Deprotected Cyclic Guanidine Product 27.





1-Ethyl-3-(4-methoxyphenyl)-1-(2-methylallyl)urea (S2). A flame-dried flask equipped with a stirbar was charged with *N*-ethyl-2-methylallylamine (1.3 mL, 10 mmol) and dichloromethane (100 mL). 4-methoxyphenyl isocyanate (1.55 mL, 12 mmol) was added to the flask and the mixture was stirred at rt for 1 h. The crude reaction mixture was concentrated *in vacuo* and purified by flash chromatography on silica gel to afford 2.43 mg (98%) of the title compound as a pale yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 7.23 (d, *J* = 8.5 Hz, 2 H), 6.82 (d, *J* = 8.5 Hz, 2 H), 6.30, (s, 1 H), 5.02 (s, br, 2 H), 3.83 (s, br, 2 H), 3.77 (s, 3 H), 3.42 (q, *J* = 7.0 Hz, 2 H), 1.79 (s, 3 H), 1.20 (t, *J* = 7.0 Hz, 3 H).



1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-one (S3): A flamedried Schlenk tube was cooled under vacuum and charged with Pd_2dba_3 (110 mg, 0.12 mmol), xantphos (139 mg, 0.24 mmol), NaOtBu (865 mg, 9.0 mmol), and 4-bromotoluene (1.5 g, 9.0 mmol). A solution of **S2** (1.5 g, 6.0 mmol) in toluene (30 mL) was added via syringe and the tube was heated to 105 °C for 3 h. The mixture was cooled to rt and saturated aqueous NH₄Cl (15 mL) and ethyl acetate (25 mL) were added. The layers were separated and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 1.96 mg (97%) of the title compound as a orange yellow oil. ¹H NMR (700 MHz, CDCl₃) δ 7.18 (d, *J* = 9.1 Hz, 2 H), 7.08 (d, *J* = 7.7 Hz, 2 H), 6.99 (d, *J* = 8.4 Hz, 2 H), 6.92 (d, *J* = 9.1 Hz, 2 H), 3.82 (s, 3 H), 3.46 (d, *J* = 8.4 Hz, 1 H), 3.37–3.32 (m, 1 H), 3.27–3.22 (m, 1 H), 2.92 (d, *J* = 13.3 Hz, 1 H), 2.84 (d, *J* = 9.1 Hz, 1 H), 2.65 (d, *J* = 13.3 Hz, 1 H), 2.31 (s, 3 H), 1.22 (s, 3 H), 1.11 (t, *J* = 7.0 Hz, 3 H);



1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine

hydrochloride (27). A flame-dried flask was cooled under a stream of N_2 and charged with **S3** (100 mg, 0.3 mmol) and toluene (2 mL). POCl₃ (0.6 mL) was added and the mixture was stirred at 100 °C until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 2 hr). The reaction mixture was cooled to rt and concentrated *in vacuo*. The crude product was dissolved in acetonitrile (10 mL) and a solution of ammonia in ethanol (15 mL, 2 M in ethanol) was added. The mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 1 hr). The reaction mixture was concentrated and dissolved in dichloromethane (5 mL). Water (5 mL) was added and the mixture was transferred to a separatory funnel. The layers were separated and the organic layer was washed with 1 M HCI (10 mL) and saturated aqueous sodium chloride (2 x 10 mL). The combined aqueous layers were extracted with dichloromethane (3 x 10 mL). The combined organics layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 70 mg (63%) of the title compound as a white solid. The spectroscopic properties of this compound were identical to that of compound **27** described above that was prepared by deprotection of **18**.

Stereochemical Analysis of Enantioenriched Cyclic Guanidine Product 18.

In order to assess the enantiomeric purity of cyclic guanidine products **18** prepared from (S)-Phanephos and (S)-BINAP, the carboamination products were converted to the corresponding Mosher amides **S4** via the two-step procedure illustrated below. The enantiomeric ratio of **18** was assigned based on the diastereomeric ratio of crude **S4** as determined by ¹H NMR analysis.





(2R)-N-(1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-ylidene)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide hydrochloride (S4 prepared from (+)-18 that was generated using (S)-Phanephos as ligand). The chiral guanidine (+)-18 prepared using (S)-Phanephos as the ligand (51.5 mg, 0.11 mmol) was deprotected with ceric ammonium nitrate (361 mg, 0.66 mmol) according to the procedure detailed above. After flash chromatography, this procedure afforded 8.0 mg (20%) of enantioenriched 27 as a brown solid. The spectroscopic properties of this compound were identical to that of racemic 27 described above. The purified nonracemic material 27 (8.0 mg, 0.02 mmol) was dissolved in dichloromethane (1 mL) and stirred at rt. NaH (2.5 mg, 0.06 mmol, 60% dispersion in mineral oil) was added and the mixture was allowed to stir at rt for 10 min. Neat (S)-(+)- α -Methoxy- α trifluoromethylphenylacetyl chloride (6 µL, 0.03 mmol) was added via syringe and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis of an aliquot removed from the reaction mixture (ca. 1 hr). Brine (2 mL) was added and the biphasic mixture was transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 4 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. This procedure afforded a crude mixture that was determined to be a 61:39 mixture of diastereomers by ¹H NMR analysis. The crude material was purified by flash chromatography on silica gel to afford 8.9 mg (77%) of the title compound as a pale brown foamy-oil and as a 57:43 mixture of diastereomers (note that product er was assigned based on dr of the crude product, as some separation of diastereomers likely occurred during purification). Data are for the mixture of isomers. ¹H NMR (500 MHz, CDCl₃) δ 7.44–7.40 (m, 3.5 H), 7.29–7.24 (m, 3.75 H), 7.23–7.16 (m, 5 H), 7.12–7.10 (m, 3.5 H), 7.05–7.02 (m, 3.5 H), 6.89–6.87 (m, 3.5 H), 3.83 (s, 5.25 H), 3.77 (d, J = 10.0 Hz, 0.75 H), 3.73 (d, J = 10.0 Hz, 1 H), 3.35-3.25 (m, 2.75 H), 3.24 (s, 3 H), 3.22 (s, 2.25 H), 3.20-3.18 (m, 0.75 H), 3.16 (d, J = 10.0 Hz, 1 H), 3.10 (d, J = 10.5 Hz, 0.75 H), 3.07–3.03 (m, 1.75 H), 2.75 (d, J = 13.5 Hz, 1 H), 2.69 (d, J = 13.5 Hz, 0.75 H), 2.32 (s, 5.25 H), 1.31 (s, 2.25 H), 1.28 (s, 3 H), 1.12–1.08 (m, 5.25 H); ¹³C NMR (125 MHz, CDCl₃) δ 167.9, 167.8, 164.4, 164.3, 159.7, 159.6, 136.9, 136.9, 135.8, 135.7, 132.2, 132.2, 131.6, 131.6, 130.2,

130.1, 129.3, 129.3, 127.9, 127.6, 127.5, 127.5, 127.4, 125.7, 123.4, 114.1, 64.5, 64.5, 55.5, 55.0, 54.7, 54.3, 44.3, 43.9, 40.2, 40.1, 24.5, 24.4, 21.0, 12.4, 12.3; ^{19}F NMR (376 MHz, CDCl₃) δ –69.56, –69.58; IR (film) 2925, 1653, 1559 cm⁻¹. MS (ESI) 554.2625 (554.2625 calcd for $C_{31}H_{34}F_3N_3O_3, M^{\star}).$



(2R)-N-(1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-ylidene)-3.3.3-trifluoro-2-methoxy-2-phenylpropanamide hydrochloride (S4 prepared from (-)-18 that was generated using (S)-BINAP as ligand). The chiral guanidine (-)-18 prepared using (S)-BINAP as the ligand (48 mg, 0.1 mmol) was deprotected with ceric ammonium nitrate (329 mg, 0.6 mmol) according to the procedure detailed above. After flash chromatography, this procedure afforded 14.4 mg (39%) of enantioenriched 27 as a brown solid. The spectroscopic properties of this compound were identical to that of compound racemic 27 described above. The purified nonracemic material 27 (14.4 mg, 0.04 mmol) was dissolved in dichloromethane (1 mL) and stirred at rt. NaH (4.8 mg, 0.12 mmol, 60% dispersion in mineral oil) was added and the mixture was allowed to stir at rt for 10 min. Neat (S)-(+)- α -Methoxy- α -trifluoromethylphenylacetyl chloride (11 µL, 0.06 mmol) was added via syringe and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis of an aliquot removed from the reaction mixture (ca. 1 hr). Brine (2 mL) was added and the biphasic mixture was transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 4 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. This procedure afforded a crude mixture that was determined to be a 48:52 mixture of diastereomers by ¹H NMR analysis. The crude material was purified by flash chromatography on silica gel to afford 10.8 mg (48%) of the title compound as a pale brown foamy-oil and as a 51:49 mixture of diastereomers. Spectroscopic data were identical to those described above (although integration ratios differed due to the differences in product distribution.

References

- (1) Harada, H.; Thalji, R. K.; Bergman, R. G.; Ellman, J. A. J. Org. Chem. 2008, 73, 6772–6779.
- (2) Donets, P. A.; Van der Eycken, E. V. Synthesis 2011, 13, 2147–2153.
- (3) Yong, Y. F.; Kowalski, J. A.; Lipton, M. A. J. Org. Chem. 1997, 62, 1540–1542.
- (4) Fell, J. B.; Coppola, G. M. Synth. Commun. 1995, 25, 43-47.
- (5) Chaudhari, P. S.; Dangate, P. S.; Akamanchi, K. G. Synlett 2010, 3065-3067.
- (6) Li, D.; Guang, J.; Zhang, W.-X.; Wang, Y.; Xi, Z. Org. Biomol. Chem. 2010, 8, 1816-1820.



S24

























STANDARD PROTON PARAMETERS Sample Name:

Data Collected on: Te-vnmrs500 Archive directory:

Sample directory:

FidFile: BPZ-2-79C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Jan 23 2013

🔆 Agilent Technologies





S36





200 180 160 140 120 100 80 60 40 20 ppm







S40









S44



Agilent Technologies

STANDARD 1H OBSERVE - profile

Sample Name:

Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: BPZ-2-124C

Pulse Sequence: CARBON (s2pul) Solvent: cdc13 Data collected on: Apr 28 2013

















S52

-69.7

-69.8

-69.9

ppm

-69.3

-69.4

-69.5

-69.6